IntroductionThe bone marrow immune microenvironment (BMME) shapes treatment response in multiple myeloma (MM), yet routine diagnostic workup primarily assesses tumor burden rather than immune competence. We developed ImmunoCast-MM, a cross-modal deep learning framework that extracts immunologically relevant signals from two examinations routinely performed at diagnosis: Wright–Giemsa-stained bone marrow aspirate smears and whole-body 18F-FDG PET/CT.MethodsThe cytomorphology branch used DinoBloom embeddings to classify individual cells across five hierarchical levels.
The PET/CT branch generated a multi-organ inflammation fingerprint from tumor, spleen, lymph node, and diffuse bone marrow compartments. A contrastive fusion module aligned the two imaging modalities with a flow cytometry reference panel and generated an Immune Dysfunction Index (IDI) along a learned effector–suppressor axis.
ImmunoCast-MM was evaluated retrospectively in 243 patients with newly diagnosed MM. Associations with flow cytometric measurements, progression-free survival, and daratumumab response were assessed, with adjustment for International Staging System stage, cytogenetic risk, and age.ResultsOn a held-out validation subset, decoded cytomorphologic indices correlated with matched flow cytometric fractions, with Spearman ρ values of 0.68–0.81 across three decoded index–panel pairs; all Benjamini–Hochberg-adjusted (p) values were (<0.001).
Frontiers in Immunology published a clinical update in Infectious Disease on 24 Jun 2026.
The item focuses on Cross-modal fusion of cytomorphology and 18F-FDG PET/CT for non-invasive bone marrow immune microenvironment decoding in multiple myeloma.
Review the original article for the full source wording and details.